Jing Li, MD, PhD, on Brain Metastases: Stereotactic Radiosurgery vs Whole-Brain Radiation Therapy
2020 ASTRO Annual Meeting
Jing Li, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results showing the use of stereotactic radiosurgery in patients with 4 to 15 brain metastases, compared with whole-brain radiotherapy, may better preserve cognitive function and minimize the interruption of systemic therapy without compromising overall survival (Abstract 41).
Jeff M. Michalski, MD, MBA, of the Washington University School of Medicine, discusses a Children’s Oncology Group study that confirmed data previously reported: Involved-field radiotherapy is noninferior to posterior fossa radiotherapy in patients with average risk-medulloblastoma. However, low-dose craniospinal irradiation is not as effective as standard-dose irradiation in younger children (Abstract 1).
Youssef Zeidan, MD, PhD, of the American University of Beirut Medical Center, discusses study findings showing that breast-conserving surgery, whole-breast irradiation, and trastuzumab offer effective local tumor control for patients with HER2-positive breast cancer. An additional radiation boost does not seem to further improve outcomes (Abstract 52).
Vinai Gondi, MD, of Northwestern Medicine Cancer Center and Northwestern Medicine Proton Center, discusses the preliminary results of an NRG Oncology study of radiotherapy dose intensification using intensity-modulated radiotherapy vs standard-dose radiotherapy with temozolomide in patients with newly diagnosed glioblastoma (Abstract 42).
Neha Vapiwala, MD, of the University of Pennsylvania, who served as a discussant for LBA1, summarizes her review of this study of patients with prostate cancer who had biochemical recurrence in the post-prostatectomy setting, who were candidates for salvage radiotherapy, and who received either conventional imaging or PET scans to help determine the course of treatment.
Alphonse G. Taghian, MD, PhD, of Massachusetts General Hospital, reviews the 10-year follow-up of a dose-escalation trial studying accelerated partial-breast irradiation and discusses the optimal dose, adverse effects, and cosmetic outcomes (Abstract 25).